Comparison of general anesthesia with new intravenous anesthetic remimazolam besilate versus propofol

Comparison of general anesthesia with new intravenous anesthetic remimazolam besilate versus propofol - Comparison of general anesthesia with new intravenous anesthetic remimazolam besilate versus propofol

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000041953

Enrollment

100

Registered

2021-10-01

Start date

2020-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

jaw deformity, jaw cyst, impacted tooth

Interventions

Remimazolam beslate is administered intravenously under general anesthesia.The basic dose is 12 mg/kg/h for introducing anesthesia and 1 mg/kg/h for maintaining anesthesia, and the dose is appropriate

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: American Society of Anesthesiologists Physical Status Classification System ASAPS1,2

Exclusion criteria

Exclusion criteria: Patients with ASAPS3 or above, under 20 years old, over 80 years old, patients taking psychiatric stabilizers, mental illness, cerebrovascular accidents, bronchial asthma (due to drug use contraindications), neuromuscular disease patients and patients with acute obstructive angle glaucoma (Contraindications for Remimazolam besilate)

Design outcomes

Primary

Measure	Time frame
Time to loss of consciousness, BIS value, blood pressure, heart rate, drug administration rate, existence of side effects	—

Countries

Japan

Contacts

Public ContactKeiko Fujii-Abe

Tsurumi University, School of Dental Medicine Department of Dental Anesthesiology

fujii-keiko@tsurumi-u.ac.jp045-580-8343

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026